Endocrine Abstracts

Background: Neuroendocrine Tumor (NET) patients are the fastest growing population of cancer patients, hence we wanted to assess if there are gaps in patient knowledge and awareness of their disease. To improve our understanding of the factors affecting patient knowledgeability, we looked at their educational level, satisfaction with educational materials provided at initial diagnosis, other sources used for awareness, and their level of accessibility to education materials ab...

Background: Neuroendocrine tumors are a rare group of cancers. The median overall survival of these patients is ~10 years, presenting a unique issue of accrued financial distress over a long period of time. We attempted to look at the potential determinants of financial distress in NET patients, focusing on their demographics, comorbidity burden, educational status and tumor symptoms.Methods: A total of 155 patients have been enrolled in the Roswell Park...

Background: With the advent of new therapeutic modalities, the overall survival of neuroendocrine tumor (NET) patients has increased. However, the impact of the symptoms, treatments on the quality of life (QoL) of the patients, accessibility to health care, and financial toxicity are underreported in the literature. We have established a prospective NET biobank to capture the burden of the disease on patients’ daily life and the impact on their QoLM...

Background: The incidence of young-onset colorectal adenocarcinoma is predicted to continue rising over the next decade. Overall, data about young onset neuroendocrine tumors (NET) is scarce. In this analysis, we sought to investigate trends and differences in survival for colorectal NET in the young-onset population and to compare this with the average onset population. In addition, we seek to compare differences between adenocarcinoma and NET in the young-onset population. <...

Background: Lanreotide is clinically effective in advanced neuroendocrine tumors (NETs). The inhibitory effect of lanreotide on tumor cells proliferation is due to binding to somatostatin receptors (SSTR1-5). It has been demonstrated that immune cells express SSTR1-5 differentially. The exact effect of somatostatin analogs (SSAs) on T cell function is not understood.Methods: In vitro and in vivo effects of lanreotide on immune cells wer...

Background: Metastatic neuroendocrine carcinomas (NECs) have a poor prognosis, and standard first-line chemotherapy combines etoposide (E) and platinum (P) has limited benefit. Currently, there is no standard second-line therapy. Irinotecan-based regimens have shown benefits; hence we explored nanoliposomal Irinotecan (nal-IRI) efficacy in this patient population.Methods: In this open-label, single-arm, multi-center Phase 2 study, advanced GEP or unknown...